You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
|
|---|---|
| Published in |
Frontiers in oncology, August 2014
|
| DOI | 10.3389/fonc.2014.00204 |
| Pubmed ID | |
| Authors |
Grzegorz J. Korpanty, Donna M. Graham, Mark D. Vincent, Natasha B. Leighl |
| Abstract |
Lung cancer remains the most lethal malignancy in the world. Despite improvements in surgical treatment, systemic therapy, and radiotherapy, the 5-year survival rate for all patients diagnosed with lung cancer remains between 15 and 20%. Newer therapeutic strategies rely on specific molecular alterations, or biomarkers, that provide opportunities for a personalized approach to specific patient populations. Classification of lung cancer is becoming increasingly focused on these biomarkers, which renders the term "non-small cell lung" cancer less clinically useful. Non-small cell lung cancer is now recognized as a complex malignancy and its molecular and genomic diversity allows for patient-centered treatment options. Here, we review advances in targeted treatment of lung adenocarcinoma with respect to five clinically relevant biomarkers - EGFR, ALK, MET, ROS-1, and KRAS. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 33% |
| United Kingdom | 1 | 11% |
| Italy | 1 | 11% |
| Unknown | 4 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 67% |
| Practitioners (doctors, other healthcare professionals) | 2 | 22% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 189 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Austria | 1 | <1% |
| Unknown | 188 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 34 | 18% |
| Student > Master | 31 | 16% |
| Researcher | 21 | 11% |
| Student > Bachelor | 19 | 10% |
| Student > Postgraduate | 18 | 10% |
| Other | 37 | 20% |
| Unknown | 29 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 49 | 26% |
| Biochemistry, Genetics and Molecular Biology | 42 | 22% |
| Agricultural and Biological Sciences | 32 | 17% |
| Chemistry | 5 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
| Other | 23 | 12% |
| Unknown | 33 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2023.
All research outputs
#2,258,657
of 25,394,764 outputs
Outputs from Frontiers in oncology
#508
of 22,440 outputs
Outputs of similar age
#22,376
of 242,921 outputs
Outputs of similar age from Frontiers in oncology
#4
of 87 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,440 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,921 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.